Viatris' Farxiga generic gets EMA committee's backing for approval in EU
Waldemarus         

A panel of the European Medicines Agency (EMA) recommended granting approval toÂ Viatris (NASDAQ:VTRS) drugÂ Dapagliflozin Viatris to treat type 2 diabetes mellitus, heart failure and chronic kidney disease.
Dapagliflozin Viatris is a generic of AstraZeneca's (NASDAQ:AZN) Forxiga, which has been authorized in the EU since November 2012. The drug is marketed asÂ Farxiga in the U.S.
The European Commission, which generally follows the opinion of the EMA's Committee for Medicinal Products for Human Use (CHMP), will now decide on the marketing authorization of the drug.